Frequently asked · Section 06
PT-141, answered: the questions people actually ask
Direct, cited answers on bremelanotide's mechanism, approval scope, dosing as studied, and the off-label male research.
What is PT-141 used for?
PT-141 (bremelanotide) is FDA-approved only for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [6][11]. Every other use — including in men and for erectile dysfunction — is off-label. The approved indication is narrow and specific, and it is the most reliable single fact to keep about the molecule.
What is PT-141?
PT-141 is the research designation for bremelanotide, a synthetic cyclic-heptapeptide analogue of alpha-MSH that activates central melanocortin MC3R/MC4R receptors [1]. It works on brain circuits tied to sexual desire and arousal rather than on blood flow, which sets it apart from erectile pills.
What is PT-141 peptide?
It is a cyclic seven-amino-acid peptide — a lactam analogue of alpha-MSH; "peptide" names its molecular class [1]. The approved drug is bremelanotide injection. Material sold as a "PT-141 research chemical" is laboratory-research-only and is not the approved finished product.
What does the PT-141 peptide do?
It activates central melanocortin receptors — chiefly MC4R — in hypothalamic and limbic circuits linked to sexual desire and arousal [1][2]. That central action is the basis for its approved HSDD indication in premenopausal women, and it is why the molecule influences desire rather than vascular blood flow.
Is PT-141 the same as bremelanotide?
Yes. PT-141 is the development and research designation; bremelanotide is the international nonproprietary name (INN) for the same molecule — the FDA-approved melanocortin receptor agonist for HSDD [6]. Two names, one compound.
What is bremelanotide?
Bremelanotide is the approved-drug name for PT-141, a melanocortin (MC3R/MC4R) receptor agonist approved in 2019 as a 1.75 mg subcutaneous as-needed injection for HSDD in premenopausal women [6][11]. It is the INN that appears on the prescribing label.
How does PT-141 work?
By agonizing melanocortin MC4R (and MC3R) receptors in hypothalamic circuits such as the medial preoptic area, engaging dopamine pathways tied to sexual desire [1][2]. It is a central mechanism, not a vascular one — the molecule acts on the neural circuitry of wanting rather than on penile blood flow.
What receptors does PT-141 act on?
Chiefly the melanocortin 4 receptor (MC4R) and, secondarily, the melanocortin 3 receptor (MC3R), both concentrated in the central nervous system [1]. MC4R in hypothalamic desire circuits is the principal target; the same receptor in appetite circuits explains the weight effects seen at high-frequency dosing.
What is a melanocortin receptor agonist?
A molecule that activates one or more of the five melanocortin receptors (MC1R-MC5R). PT-141 targets the central MC3R/MC4R subtypes that influence sexual desire and appetite [1]. The class also includes signals that affect pigment, which is why repeated dosing can darken skin.
Does PT-141 increase testosterone?
No. PT-141 does not act through the hypothalamic-pituitary-gonadal axis and does not directly raise testosterone; it works through central melanocortin signaling [1]. This is a common point of confusion — the molecule changes desire via brain receptors, not via hormone levels.
Does PT-141 work through the brain or through blood flow?
Through the brain. It activates melanocortin MC4R/MC3R receptors in hypothalamic circuits governing sexual desire and arousal [1][2], unlike PDE-5 inhibitors, which act peripherally on vascular smooth muscle. The readout is desire and arousal, not penile blood flow — a central mechanism, not a vascular one.
How is PT-141 different from PDE-5 inhibitors?
PT-141 is a central melanocortin receptor agonist acting on brain circuits of sexual motivation; PDE-5 inhibitors act peripherally on penile blood flow [1][2]. Early research even combined the two for an enhanced erectile response [7], because the mechanisms are complementary rather than competing.
Does PT-141 nasal spray work?
An intranasal formulation was studied early in men and produced a statistically significant erectile response above 7 mg [1]. It was then discontinued for pharmacokinetic variability in favor of the approved subcutaneous route [6]. No current approved product is a nasal spray.
What does PT-141 do for men?
In early-phase research, PT-141 produced dose-dependent erectile activity in men with erectile dysfunction [1]. Male and erectile use is off-label and investigational — not approved and not established. The most-cited male erectile data is decades old, and current development is at the Phase 2 stage.
Is PT-141 approved for men?
No. Bremelanotide's only FDA-approved indication is HSDD in premenopausal women [6][11]. Use in men is off-label. A Phase 2 study of co-administration with a PDE-5 inhibitor for erectile dysfunction is ongoing, but it is investigational, not an approval.
Is PT-141 better than PDE-5 inhibitors for erectile dysfunction?
The research doesn't frame them as better-or-worse. PT-141 acts centrally on desire circuits; PDE-5 inhibitors act peripherally on penile blood flow [1][2]. The two have been studied in combination — including an ongoing Phase 2 co-administration trial for PDE-5-inhibitor non-responders — rather than head-to-head.
Why is PT-141 being studied with a PDE-5 inhibitor?
Because the mechanisms are complementary — central desire-and-arousal signaling plus peripheral blood flow. An early study found combining low-dose intranasal PT-141 with sildenafil enhanced the erectile response [7]. A Phase 2 co-administration program is now underway for non-responders. It is investigational, not approved.
What is the PT-141 dosage?
As a finding only: the label specifies 1.75 mg subcutaneously as needed, no more than one dose per 24 hours and no more than 8 per month [6]. That is the studied regimen for the approved indication, not a recommendation for any reader to follow.
How much PT-141 should I take?
This site does not recommend a dose for any individual. The approved label and the RECONNECT trials used 1.75 mg subcutaneous as-needed [3][6]; dosing decisions belong to a qualified prescriber. We report what was studied, not what anyone should do.
How much PT-141 to inject?
Reported as a finding: the approved subcutaneous dose studied was 1.75 mg as-needed, and Phase 2 dose-finding evaluated 0.75, 1.25, and 1.75 mg [3][6]. This is a record of the trials, not a protocol to follow.
What is the PT-141 dosage for women?
In the approved indication — premenopausal women with HSDD — the studied and labeled dose is 1.75 mg subcutaneously as needed, at least 45 minutes before anticipated sexual activity [6]. Reported as a finding, not as advice for any individual.
How do you reconstitute PT-141?
The approved product is a pre-filled single-dose subcutaneous autoinjector, so no reconstitution is involved [6]. Lyophilized "research chemical" material is a different, unapproved form, and this site offers no preparation protocol for it.